Last reviewed 2026-04-22 · How we verify

Arm D: FOLFIRI or FOLFOX plus CETUXIMAB

Arm D: FOLFIRI or FOLFOX plus CETUXIMAB is a Chemotherapy combination with monoclonal antibody Small molecule drug developed by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. It is currently in Phase 3 development for Metastatic colorectal cancer, KRAS wild-type, Advanced colorectal cancer. Also known as: FOLFIRI or FOLFOX plus CETUXIMAB.

This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth.

This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth. Used for Metastatic colorectal cancer, KRAS wild-type, Advanced colorectal cancer.

At a glance

Mechanism of action

FOLFIRI (fluorouracil, leucovorin, irinotecan) and FOLFOX (fluorouracil, leucovorin, oxaliplatin) are standard chemotherapy backbones that inhibit DNA synthesis and cause cell death. Cetuximab is a chimeric monoclonal antibody targeting EGFR, which blocks ligand-induced receptor activation and downstream proliferation signaling. The combination leverages both cytotoxic chemotherapy and targeted EGFR inhibition to enhance anti-tumor activity.

Approved indications

• Metastatic colorectal cancer, KRAS wild-type
• Advanced colorectal cancer

Common side effects

• Neutropenia
• Diarrhea
• Nausea/vomiting
• Acneiform rash
• Fatigue
• Mucositis

Key clinical trials

• Sequential Treatment Strategy for Metastatic Colorectal Cancer (PHASE3)
• Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (PHASE2)
• Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (NA)
• FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Arm D: FOLFIRI or FOLFOX plus CETUXIMAB CI brief — competitive landscape report
• Arm D: FOLFIRI or FOLFOX plus CETUXIMAB updates RSS · CI watch RSS
• Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS portfolio CI

Frequently asked questions about Arm D: FOLFIRI or FOLFOX plus CETUXIMAB

Related

• Drug class: All Chemotherapy combination with monoclonal antibody drugs
• Target: All drugs targeting EGFR (epidermal growth factor receptor)
• Manufacturer: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Metastatic colorectal cancer, KRAS wild-type
• Indication: Drugs for Advanced colorectal cancer
• Also known as: FOLFIRI or FOLFOX plus CETUXIMAB
• Compare: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB vs similar drugs
• Pricing: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB cost, discount & access